Back to results
US 9,751,931 B2Granted
Hepatitis C virus neutralizing antibodies and methods
AssigneesThe United States of America, as represented by the Secretary, Department of Health and Human Services, Federal Budgetary Research Institution State Research Center of Virology and Biotechnology “Vector”
InventorsMarian Elaine Major, Alla Kachko, Galina Vadimovna Kochneva
Life of this patent
Estimating the term…
Abstract
Novel epitope regions on hepatitis C virus E1E2 glycoprotein that induce a neutralizing antibody response in vivo are identified. Cross-neutralizing monoclonal antibodies that bind specifically to the epitopes are disclosed.
Claims13
An isolated antibody, which binds specifically to an epitope of hepatitis C virus (HCV),
- wherein the epitope is contained within amino acid residues 496-515 of the HCV polyprotein set forth in SEQ ID NO:1,
- the antibody comprising
- a heavy chain variable region comprising complementary determining region (CDR) 1 amino acid sequence of residues 27-34 (GFTFSSFG) of SEQ ID NO:3, CDR2 amino acid sequence of residues 52-59 (ISSGSSTL) of SEQ ID NO:3, and CDR3 amino acid sequence of residues 98-105 (DHGHRLLK) of SEQ ID NO:3, and
- a light chain variable region comprising CDR1 amino acid sequence of residues 27-32 (QDVGTA) of SEQ ID NO:5, CDR2 amino acid sequence of residues 50-52 (WAS) of SEQ ID NO:5, and CDR3 amino acid sequence of residues 89-97 (QQYSNFPLT) of SEQ ID NO:5.
1 more element
Dependencies are inferred from the claim text.